Dermatology and cosmetics company Pierre Fabre Laboratories has bought oncology specialist Vertical Bio, thus adding VERT-002 to its discovery pipeline.
The French firm has a long track record in the treatment of cancer, beginning with the launch of a chemotherapy product several decades ago.
Building on this, the group has now made oncology its top strategic priority, focusing 80% of its R&D spend in this area, leading to a more than doubling of revenues from 2019, up to around half a billion dollars.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze